Nancy E Gray

US Patent:

6953808, Oct 11, 2005

Filed:

Jan 14, 2004

Appl. No.:

10/757059

Inventors:

Nancy M. Gray - Marlborough MA, US

Assignee:

Sepracor Inc. - Marlborough MA

International Classification:

A61K031/44

US Classification:

514338

Abstract:

Methods and compositions are disclosed utilizing optically pure (−) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Pantoprazole is an inhibitor of H release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

US Patent:

20010008899, Jul 19, 2001

Filed:

Feb 14, 2001

Appl. No.:

09/783683

Inventors:

Nancy Gray - Marlborough MA, US

International Classification:

A61K031/44

US Classification:

514/338000, 424/449000

Abstract:

Methods and compositions are disclosed utilizing optically pure (-) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (-) isomer is also useful for the treatment of gastroesophageal reflux. (-) Pantoprazole is an inhibitor of Hrelease and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

US Patent:

20010009917, Jul 26, 2001

Filed:

Mar 5, 2001

Appl. No.:

09/800059

Inventors:

Nancy Gray - Marlborough MA, US

International Classification:

A61K031/47

US Classification:

514/310000

Abstract:

Methods and compositions are disclosed utilizing optically pure (+)-zileuton for the treatment of asthma, rheumatoid arthritis and ulcerative colitis in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of zileuton. (+)-Zileuton is an inhibitor of 5-lipoxygenase and is therefore useful in the treatment of other conditions related to elevated leukotriene levels (+)-Zileuton is also an antioxidant and is therefore useful in treating or preventing atherosclerosis.

US Patent:

20020019420, Feb 14, 2002

Filed:

Sep 7, 2001

Appl. No.:

09/948983

Inventors:

Nancy Gray - Marlborough MA, US

Assignee:

Sepracor Inc. - Marlborough MA

International Classification:

A61K031/4439

US Classification:

514/339000

Abstract:

Methods and compositions are disclosed utilizing optically pure (+) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (+) isomer is also useful for the treatment of gastroesophageal reflux. (+) Pantoprazole is an inhibitor of H release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

US Patent:

20030086968, May 8, 2003

Filed:

Sep 26, 2002

Appl. No.:

10/256518

Inventors:

Nancy Gray - Marlborough MA, US

Assignee:

SEPRACOR INC. - Marlborough MA

International Classification:

A61K031/4439

US Classification:

424/465000, 514/338000

Abstract:

Methods and compositions are disclosed utilizing optically pure (-) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (-) isomer is also useful for the treatment of gastroesophageal reflux. (-) Pantoprazole is an inhibitor of H release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

US Patent:

55082793, Apr 16, 1996

Filed:

Mar 7, 1994

Appl. No.:

8/206764

Inventors:

Nancy M. Gray - Marlboro MA

Assignee:

Sepracor, Inc. - Marlborough MA

International Classification:

A61K 31495

US Classification:

514254

Abstract:

Methods are disclosed utilizing the optically pure (+) isomer of doxazosin. This compound is a potent drug for the treatment of benign prostatic hyperplasia while avoiding the concomitant liability of hypotensive effects associated with the racemic mixture of doxazosin.

US Patent:

56271832, May 6, 1997

Filed:

Mar 26, 1996

Appl. No.:

8/622617

Inventors:

Nancy M. Gray - Marlboro MA

Assignee:

Sepracor, Inc. - Marlborough MA

International Classification:

A61K 31495

US Classification:

514255

Abstract:

Methods are disclosed utilizing optically pure (+) cetirizine for the treatment of urticaria in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine.

US Patent:

59554770, Sep 21, 1999

Filed:

Nov 21, 1996

Appl. No.:

8/752984

Inventors:

Nancy M. Gray - Marlborough MA
James W. Young - Palo Alto CA

Assignee:

Sepracor Inc. - Marlborough MA

International Classification:

A61K 31445

US Classification:

514327

Abstract:

The optically pure (-) isomer of cisapride is useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (-) cisapride as a prokinetic agent, such as gastroparesis, constipation, post-operative ileus, and intestinal pseudo-obstruction, without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (-) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system.